BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push ...

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Shares in Bausch & Lomb surged on Monday amid speculation that the North American contact lens and eye care products supplier ...

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...